782-H Effects of an AI generated personalized neopeptide-based immunotherapy, EVX-01, in combination with pembrolizumab in patients with metastatic melanoma: a clinical trial update

• Paolo A Ascierto,
• Georgina V Long,
• Michael Chisamore,
• Paola Queirolo,
• Adnan Khattak,
• Anders Jespersen,
• Daniela Kleine-Kohlbrecher,
• Nadia Viborg,
• Mads Lausen,
• Stine F Thorsen,
• Thomas Trolle

Affiliations

Paolo A Ascierto

2Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy

Georgina V Long

7Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia

Michael Chisamore

4Merck and Co., Inc., Rahway, NJ, USA

Paola Queirolo

3IEO European Institute of Oncology IRCCS, Milan, Italy

Adnan Khattak

1Hollywood Private Hospital and Edith Cowan University, Perth, Western Australia, Australia

Anders Jespersen

6Evaxion Biotech, Hoersholm, Zealand, Denmark

Daniela Kleine-Kohlbrecher

5Evaxion Biotech, Horsholm, Denmark

Nadia Viborg

6Evaxion Biotech, Hoersholm, Zealand, Denmark

Mads Lausen

6Evaxion Biotech, Hoersholm, Zealand, Denmark

Stine F Thorsen

5Evaxion Biotech, Horsholm, Denmark

Thomas Trolle

6Evaxion Biotech, Hoersholm, Zealand, Denmark